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OBJECTIVES: Define the treatment patterns and associated costs to treat meta-
static prostate cancer in Brazilian private health care system. METHODS: In a na-
tionwide oncology claims database of 3.5 million lives, from August 2010 to July
2011, 67 patients were identifiedwithmetastatic prostate cancer using chemother-
apy. Patients using hormone therapy were excluded. The database gathered infor-
mation regarding the treatment patients were submitted, to average duration and
medication dosage. RESULTS: Patients were on average 71 years old, weighted 78
kilograms and measured 1.70 meters. Among the 67 patients, only 5 (7%) were
submitted to first line treatment with mitoxantrone and 62 (93%) with docetaxel;
58% of all patients took a second line treatment. From the 62 patients that started
with docetaxel (121.5 mg average dose for each of the 6.5 cycles (21days)), 28 had a
second line treatment with mitoxantrone (20mg average dose for each of the 3.9
cycles (21days)) with total average cost/patient of R$ 39,698 (USD 22,056); 7 were
retreated with docetaxel (60mg average dose for each of the 6 cycles (7days)). From
the 5 patients that started with mitoxantrone (20.6mg average dose for each of the
3.2 cycles (21 days)), 4 continued the treatment with docetaxel (60mg average dose
for each of the 3 applications (21 days)) with a total average cost/patient of R$ 12,795
(USD 7,107). CONCLUSIONS: The database suggests that docetaxel is the most
commonly used first line treatment to metastatic prostate cancer in the Brazilian
private health care system. Forty-two percent of the patientswere not submitted to
a second pattern in the period studied, being that 18% of the ones that had a second
line treatment were retreated with the same medication (docetaxel).
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OBJECTIVES: Treatment of bonemetastases secondary to prostate cancer typically
involves different provider types and a combination of surgery, radiation, and
pharmaceutical treatment. This study evaluated treatment patterns and costs for
patients with bone metastases secondary to prostate cancer. Which providers had
patientswith bonemetts that increased costs in surgery, radiation and chemother-
apy compared to no bonemetts?METHODS: Continuously enrolled patients in the
MarketScan database between January 2004 and December 2010 with evidence of
bone metastases (ICD9 code 198.5 or treatment with one of the following medica-
tions: zolderonic acid, pamidronate, or demosumab) were included. The relation-
ship between patterns of care regarding physician specialty, type of therapy and
cost of treatment were assessed. RESULTS: Total of 4493 patients had evidence of
bone metastases. Most patients (n2633, 59%) had both an urologist and a radiol-
ogist involved in their care. Common combinations of providers were urologist and
radiologist (U&R, 22%); urologist, radiologist, and surgeon (U, R&S, 21%), and urol-
ogist, radiologist, and oncologist (U, R&O, 17%). A majority of patient were pre-
scribed hormone therapy (89%) and 76% were prescribed steroid agents (mostly
glucocorticoids). Half of the population received radiation therapy (n2274, 51%)
and 1,838 (41%) received surgery related to their prostate cancer. Significant differ-
ences in total cost, depending on the mix of specialists involved in care: U&R:
$22,133; U, R&S: $28,305; and U, R&O: $34,366 (p0.001 for all pairwise compari-
sons). Common treatment combinations were also associated with significantly
different total costs: patients receiving steroids, radiation, chemotherapy, and hor-
mone treatment cost the most (mean: $47,914) while patients steroids, surgery,
chemotherapy, and hormone therapy cost the least (mean: $31,612).
CONCLUSIONS: Significant variation in patterns of care and total costs for patients
whohave bonemetastases secondary to prostate cancer. Additional studies should
examine the potential drivers of this variation and strategies to maximize cost-
effectiveness.
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OBJECTIVES: Previous studies documenting the clinical and economic burden of
prostate cancer (PCa) have highlighted that a substantial proportion of PCa care is
completed in the inpatient hospital setting. No studies to date, however, have
documented specific patterns of care within the inpatient setting. This study eval-
uated treatments and the associated cost of care for PCa patients treated in an
inpatient setting. METHODS: Patients in the Premier Hospital Database between
January 2006 andDecember 2010 treated in an inpatient setting for PCa (ICD9Codes
185 and 233.4) were included. Patients were required to be40 years of age with no
additional cancers. Utilization of PCa-specific treatments and costs across relevant
inpatient cost centers were assessed and described. RESULTS: There were 88,151
hospitalizations ofmen treated for PCa in an inpatient setting. Themean age of the
sample was 69 years, with 68% being Caucasian. The average hospitalization cost
was $12,286 for 4 days of stay. The most common treatments provided were sur-
gery (57%), miscellaneous drug therapy (39%), hormone therapy (30%), and radia-
tion treatment (4%). Accordingly, approximately 26% of costs were associated with
surgery, and 31% were associated with room and board; pharmaceuticals ac-
counted for 8% of costs. CONCLUSIONS:Men treated for PCa in an inpatient setting
averaged $4516 per day for approximately 4 days, with surgery and miscellaneous
drug therapy being the most frequently used inpatient treatments.
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OBJECTIVES: This study examined total health care expenditures in newly diag-
nosed subjects with colorectal cancer (CRC) over time and by lines of therapy
received.METHODS: Patients aged 18-years and older when newly diagnosed with
CRC between January 1, 2005 and June 31, 2009 were identified using a large, US-
based administrative medical claims (MarketScan) database. Patients were identi-
fied with CRC if they had an ICD-9-CM claim for a primary diagnosis of colon or
rectal cancer on 2 different days but within 180 days of each other. At least 6
months of patient history prior to CRC diagnosis and at least 1-year post-index
continuous enrollment was required. Patients were followed from initial CRC di-
agnosis (index date) to disenrollment or June 31, 2010. Chemotherapy and biologic
treatments over time were analyzed to identify lines of therapy. Total health care
costs included costs associatedwith CRC and other comorbidities. Univariate anal-
yses were performed to examine changes in costs over time and with increasing
lines of therapy. RESULTS:A total of 23,547 subjectswere includedwith amean age
of 65.3 years, 49% were over 65 years, and 52% were males. They were predomi-
nately from the South (40%) and the Midwest region (36%) andmajority (54%) were
enrolled in a preferred provider organization plan. 63% of the subjects received no
systemic treatment for CRC and 17%, 13%, and 7% received 1st line only, 2nd line
only and 3rd lines of treatment for CRC, respectively. Themean annualized costs
increased from $20,785 to $50,255 for those diagnosed in 2005 to 2009 (p-value 
0.001). Themean annualized costs for those receiving 1st line only, 2nd line only and
3rd  lines of treatment were $46,277, $69,244, and $108,819, respectively.
CONCLUSIONS: Annualized total health care costs in newly diagnosed CRC sub-
jects more than doubled from 2005 to 2009 growing faster than medical inflation.
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OBJECTIVES: Prostate cancer is the most frequent non skin cancer in men in west
European countries. The first line treatment in metastatic prostate cancer is hor-
monal therapy, however in 18-24 months it slowly turns over into metastatic hor-
mone resistant prostate cancer (mHRPC). The aim of this analysis was to charac-
terize the economic value of cabazitaxel in second line treatment of mHRPC.
METHODS: A benchmarking analysis was performed, comparing cabazitaxel with
other chemotherapeutic regimes used in second line treatment in Europe. As com-
parators we used drugs registered between 1.1.2004–18.1.2011 by EMA (according
European public assessment report EPAR) for second line treatment of oncologic
diseases. Generic products (as for example docetaxel, topotekan, talidomid, tem-
ezolomid) were not taken into account. As outcome data we used the information
about overall survival from the last analysis, if it was possible intention to treatwas
used. These data was gathered from EPAR and Summary product characteristic
and given into context with market prices, what allowed direct analysis of costs
and outcomes. The total costs for therapy were counted according the median of
therapy duration, dosing and price per milligram. As example we used prices in
Spain. RESULTS: Together 25 substances were detected, in between them orphan
medical products as well. Cabazitaxel demonstrated the second best benefit in
overall survival (cetuximab over the best supportive care HR0.51 [0.41- 0.75,
p0.0001, cabazitaxel over mitoxantrone HR 0.7 [0.59-0.83] p0.0001). According
the price cabazitaxel reached the sixth rank. The price for one vial was 3833 euro
and the price for one patient was 22 998 euro. CONCLUSIONS: The price versus
overall survival hazard ratio comparison detected cabazitaxel as the second sub-
stance, mostly reducing risk of death and thus with costs which are comparable
with other second line treatments in oncology.
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OBJECTIVES: The ENESTnd study showed that in newly-diagnosed patients with
PhCML-CP nilotinib (300mg BID) had greater efficacy than imatinib (400mgQD) in
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